HOLON, Israel, Feb. 8, 2017 /PRNewswire/ -- Compugen Ltd.
(NASDAQ: CGEN), a leader in predictive discovery and development of
first-in-class therapeutics for cancer immunotherapy, announced
today that the Company will release its fourth quarter and full
year 2017 financial results on Wednesday,
February 21, 2018 before the U.S. financial markets open.
Management will host a live webcast to review the results and
provide a corporate update at 10:00 AM
ET.
To access the live conference call by telephone, please dial
1-888-668-9141 from the U.S.,
or +972-3-918-0610 internationally. The call will also be available
via live webcast through Compugen's website, located at the
following link. Following the live audio webcast, a replay will be
available on the Company's website.
About Compugen
Compugen is a therapeutic discovery and
development company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: +1-212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-fourth-quarter-and-full-year-2017-conference-call-scheduled-for-wednesday-february-21-2018-at-1000-am-et-300595696.html
SOURCE Compugen Ltd.